Published in Drug Discov Today on November 21, 2012
Hydrogen/deuterium exchange mass spectrometry for probing higher order structure of protein therapeutics: methodology and applications. Drug Discov Today (2013) 1.13
Structural and antigenic definition of hepatitis C virus E2 glycoprotein epitopes targeted by monoclonal antibodies. Clin Dev Immunol (2013) 0.95
Current approaches to fine mapping of antigen-antibody interactions. Immunology (2014) 0.82
Peptide-based vaccinology: experimental and computational approaches to target hypervariable viruses through the fine characterization of protective epitopes recognized by monoclonal antibodies and the identification of T-cell-activating peptides. Clin Dev Immunol (2013) 0.80
HCV E2 core structures and mAbs: something is still missing. Drug Discov Today (2014) 0.79
Hydrogen/deuterium exchange mass spectrometry applied to IL-23 interaction characteristics: potential impact for therapeutics. Expert Rev Proteomics (2015) 0.77
The influence of adnectin binding on the extracellular domain of epidermal growth factor receptor. J Am Soc Mass Spectrom (2014) 0.76
Comparative analysis of evolutionarily conserved motifs of epidermal growth factor receptor 2 (HER2) predicts novel potential therapeutic epitopes. PLoS One (2014) 0.75
Human monoclonal antibodies as a new class of antiinfective compounds. Clin Dev Immunol (2013) 0.75
Mapping the Energetic Epitope of an Antibody/Interleukin-23 Interaction with Hydrogen/Deuterium Exchange, Fast Photochemical Oxidation of Proteins Mass Spectrometry, and Alanine Shave Mutagenesis. Anal Chem (2017) 0.75
The era of molecular and other non-culture-based methods in diagnosis of sepsis. Clin Microbiol Rev (2010) 2.90
Molecular diagnosis of sepsis in neutropenic patients with haematological malignancies. J Med Microbiol (2008) 2.02
Identification of a broadly cross-reacting and neutralizing human monoclonal antibody directed against the hepatitis C virus E2 protein. J Virol (2007) 1.77
Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL. J Antimicrob Chemother (2011) 1.66
Two-year prospective study of single infections and co-infections by respiratory syncytial virus and viruses identified recently in infants with acute respiratory disease. J Med Virol (2008) 1.58
Destructive extraction of phospholipids from Escherichia coli membranes by graphene nanosheets. Nat Nanotechnol (2013) 1.51
Long-term survival and virus production in human primary macrophages infected by human immunodeficiency virus. J Med Virol (2002) 1.49
Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study). AIDS (2006) 1.41
Comparative evaluation of the Bruker Biotyper and Vitek MS matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry systems for identification of yeasts of medical importance. J Clin Microbiol (2013) 1.36
Mini-FLOTAC, an innovative direct diagnostic technique for intestinal parasitic infections: experience from the field. PLoS Negl Trop Dis (2013) 1.29
Persistent symptomless human metapneumovirus infection in hematopoietic stem cell transplant recipients. J Infect Dis (2006) 1.26
Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies. AIDS (2009) 1.25
Mini-FLOTAC and Kato-Katz: helminth eggs watching on the shore of Lake Victoria. Parasit Vectors (2013) 1.17
The role of infections and coinfections with newly identified and emerging respiratory viruses in children. Virol J (2012) 1.17
Potential impact of a microarray-based nucleic acid assay for rapid detection of Gram-negative bacteria and resistance markers in positive blood cultures. J Clin Microbiol (2014) 1.16
Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir. J Infect Dis (2011) 1.15
Hepatitis C virus (HCV) infection may elicit neutralizing antibodies targeting epitopes conserved in all viral genotypes. PLoS One (2009) 1.10
Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group. New Microbiol (2012) 1.10
Delayed neuropsychological sequelae after carbon monoxide poisoning: predictive risk factors in the Emergency Department. A retrospective study. Scand J Trauma Resusc Emerg Med (2011) 1.09
A novel efflux system in inducibly erythromycin-resistant strains of Streptococcus pyogenes. Antimicrob Agents Chemother (2002) 1.08
Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group. New Microbiol (2010) 1.06
Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir. J Antimicrob Chemother (2010) 1.04
Molecular mycological diagnosis and correct antimycotic treatments. J Clin Microbiol (2005) 1.02
Long-term study on symptomless human metapneumovirus infection in hematopoietic stem cell transplant recipients. New Microbiol (2007) 1.01
Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment. Antimicrob Agents Chemother (2004) 1.00
Persistent replication of severe acute respiratory syndrome coronavirus in human tubular kidney cells selects for adaptive mutations in the membrane protein. J Virol (2008) 1.00
A potential role for monoclonal antibodies in prophylactic and therapeutic treatment of influenza. Antiviral Res (2011) 0.98
A human monoclonal antibody with neutralizing activity against highly divergent influenza subtypes. PLoS One (2011) 0.97
Molecular epidemiology of KI and WU polyomaviruses in infants with acute respiratory disease and in adult hematopoietic stem cell transplant recipients. J Med Virol (2010) 0.97
Monoclonal antibodies isolated from human B cells neutralize a broad range of H1 subtype influenza A viruses including swine-origin Influenza virus (S-OIV). Virology (2010) 0.97
Phage display-based strategies for cloning and optimization of monoclonal antibodies directed against human pathogens. Int J Mol Sci (2012) 0.96
Hepatitis C virus (HCV)-driven stimulation of subfamily-restricted natural IgM antibodies in mixed cryoglobulinemia. Autoimmun Rev (2008) 0.96
Structural and antigenic definition of hepatitis C virus E2 glycoprotein epitopes targeted by monoclonal antibodies. Clin Dev Immunol (2013) 0.95
Inhibition of hepatitis C virus nonstructural protein, helicase activity, and viral replication by a recombinant human antibody clone. Am J Pathol (2004) 0.95
Increased sensitivity of SARS-coronavirus to a combination of human type I and type II interferons. Antivir Ther (2004) 0.94
Cross-reactive pseudovirus-neutralizing anti-envelope antibodies coexist with antibodies devoid of such activity in persistent hepatitis C virus infection. Virology (2004) 0.94
Perspectives for the utilization of neutralizing human monoclonal antibodies as anti-HCV drugs. J Hepatol (2008) 0.93
Multicenter comparative study of Epstein-Barr virus DNA quantification for virological monitoring in transplanted patients. J Clin Virol (2010) 0.93
Transmission in vitro of hepatitis C virus from persistently infected human B-cells to hepatoma cells by cell-to-cell contact. J Med Virol (2006) 0.92
Coronaviridae and SARS-associated coronavirus strain HSR1. Emerg Infect Dis (2004) 0.92
Processivity and drug-dependence of HIV-1 protease: determinants of viral fitness in variants resistant to protease inhibitors. AIDS (2003) 0.92
Mini-FLOTAC, Kato-Katz and McMaster: three methods, one goal; highlights from north Argentina. Parasit Vectors (2014) 0.92
Molecular diagnosis of polymicrobial sepsis. J Clin Microbiol (2009) 0.92
A non-VH1-69 heterosubtypic neutralizing human monoclonal antibody protects mice against H1N1 and H5N1 viruses. PLoS One (2012) 0.91
Risks of "blind" automated identification systems in medical microbiology. J Clin Microbiol (2013) 0.90
Molecular cloning of the first human monoclonal antibodies neutralizing with high potency swine-origin influenza A pandemic virus (S-OIV). New Microbiol (2009) 0.89
Neutralization interfering antibodies: a "novel" example of humoral immune dysfunction facilitating viral escape? Viruses (2012) 0.88
Anti-hepatitis C virus E2 (HCV/E2) glycoprotein monoclonal antibodies and neutralization interference. Antiviral Res (2012) 0.87
Natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med (2012) 0.87
In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir. J Antimicrob Chemother (2013) 0.87
Molecular epidemiology and pathogenic potential of underdiagnosed human papillomavirus types. BMC Microbiol (2008) 0.86
New therapeutic options for HCV infection in the monoclonal antibody era. New Microbiol (2012) 0.86
Dynamic features of the selective pressure on the human immunodeficiency virus type 1 (HIV-1) gp120 CD4-binding site in a group of long term non progressor (LTNP) subjects. Retrovirology (2009) 0.86
Anti-HIV-1 response elicited in rabbits by anti-idiotype monoclonal antibodies mimicking the CD4-binding site. PLoS One (2008) 0.85
Molecular and cellular determinants of cell-to-cell transmission of HCV in vitro. J Med Virol (2007) 0.85
Pregnancy and H1N1 infection. Lancet (2009) 0.85
Influenza B-cells protective epitope characterization: a passkey for the rational design of new broad-range anti-influenza vaccines. Viruses (2012) 0.84
HIV-1 replication capacity and genotype changes in patients undergoing treatment interruption or lamivudine monotherapy. J Med Virol (2008) 0.84